# Enanta Pharmaceuticals Inc (ENTA)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/enanta-pharmaceuticals-inc/ JSON: https://steadybase.io/company/enanta-pharmaceuticals-inc.json Checked Nov 10, 2026. Latest filing read: Aug 12, 2026.

## Company

- Legal name: ENANTA PHARMACEUTICALS INC
- Ticker: ENTA (Nasdaq)
- SEC CIK: 0001177648
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Watertown, MA
- Fiscal year ends: September 30
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: enanta.com
- LinkedIn: https://www.linkedin.com/company/enanta-pharmaceuticals
- Next earnings date: Nov 16, 2026

## Key facts

- Revenue: $65.3M for the fiscal year ended Sep 30, 2025 (10-K filed Nov 19, 2025). Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/0001193125-25-288121-index.html
- Operating income: -$85.3M for the fiscal year ended Sep 30, 2025 (10-K filed Nov 19, 2025). Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/0001193125-25-288121-index.html
- Net income: -$81.9M for the fiscal year ended Sep 30, 2025 (10-Q filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/0001193125-26-345719-index.html
- SG&A: $43.9M for the fiscal year ended Sep 30, 2025 (10-K filed Nov 19, 2025). Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/0001193125-25-288121-index.html
- Employees: 120 as of Sep 30, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Shares outstanding: 29,125,402 as of Aug 7, 2026 (10-Q filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/0001193125-26-345719-index.html
- Auditor: Pricewaterhousecoopers LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm

## Business

We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.S.)S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET ® was also approved as the first and only treatment for acute HCV infection in June 2025.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Sep 30, 2025 | $65.3M | -$85.3M | -$81.9M | $43.9M |
| Sep 30, 2024 | $67.6M | -$121.7M | -$116.0M | $57.9M |
| Sep 30, 2023 | $79.2M | -$137.2M | -$133.8M | $52.9M |
| Sep 30, 2022 | $86.2M | -$123.8M | -$121.8M | $45.5M |
| Sep 30, 2021 | $97.1M | -$109.6M | -$79.0M | $32.5M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/enanta-pharmaceuticals-inc.json

## Officers and directors

- Jay R. Luly, President and CEO. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/0002064832-26-000006-index.htm
- Scott T. Rottinghaus, Chief Medical Officer. LinkedIn: https://linkedin.com/in/scottrottinghaus. Source: Form 4 filed Aug 10, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000266/0002064832-26-000266-index.htm
- Brendan Luu, Chief Business Officer. LinkedIn: https://linkedin.com/in/brendanluu. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000014/0002064832-26-000014-index.htm
- Matthew Paul Kowalsky, Chief Legal Officer. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/0002064832-26-000016-index.htm
- Tara Lynn Kieffer, Chief Product Strategy Officer. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000012/0002064832-26-000012-index.htm
- Yat Sun Or, Chief Scientific Officer. Source: Form 4 filed Feb 13, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000206483226000008/0002064832-26-000008-index.htm
- Kathleen S. Capps, Executive Director of Accounting, Controller. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Harry R. Trout III, Vice President, Finance (Principal Financial Office r). LinkedIn: https://linkedin.com/in/harry-trout-mba-6869106. Source: 10-Q filed Aug 12, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/enta-ex31_2.htm
- Bruce L.A. Carter, Ph.D., Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Kristine Peterson, Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Lesley Russell, MB. Ch.B., MRCP, Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Mark G. Foletta, Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Terry Vance, Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Yujiro S. Hata, Director. Source: 10-K filed Nov 19, 2025, https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- Scott T. Rottinghaus, M.D., Named in proxy. Source: DEF 14A filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000119312526022558/enta-20260126.htm
- Tara L. Kieffer, Ph.D., Named in proxy. Source: DEF 14A filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000119312526022558/enta-20260126.htm
- Terry C. Vance, Board member (per proxy). Source: DEF 14A filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000119312526022558/enta-20260126.htm
- Yat Sun Or, Ph.D., Named in proxy. Source: DEF 14A filed Jan 26, 2026, https://www.sec.gov/Archives/edgar/data/1177648/000119312526022558/enta-20260126.htm

## Recent 8-K events

- Oct 29, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
- Oct 28, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526435092/d160214d8k.htm
- Aug 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm
- Jul 2, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526294837/d123412d8k.htm
- Jun 23, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm
- Jun 18, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604d8k.htm
- May 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526216735/enta-20260511.htm
- Mar 26, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/enta-20260320.htm
- Mar 12, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526104109/enta-20260311.htm
- Feb 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1177648/000119312526042812/enta-20260209.htm

## Insider trades (Form 4)

- Dec 5, 2025: Kathleen S. Capps (See Remarks) sold 323 shares, about $4,596. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000070/0002064832-25-000070-index.htm
- Dec 5, 2025: Harry R. Trout III (See Remarks) sold 542 shares, about $7,713. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000067/0002064832-25-000067-index.htm
- Dec 5, 2025: Scott T. Rottinghaus (Chief Medical Officer) sold 798 shares, about $11,356. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000065/0002064832-25-000065-index.htm
- Dec 5, 2025: Brendan Luu (Chief Business Officer) sold 1,394 shares, about $19,837. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000063/0002064832-25-000063-index.htm
- Dec 5, 2025: Tara Lynn Kieffer (Chief Product Strategy Officer) sold 2,106 shares, about $29,968. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000061/0002064832-25-000061-index.htm
- Dec 5, 2025: Yat Sun Or (Chief Scientific Officer) sold 2,390 shares, about $34,010. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000059/0002064832-25-000059-index.htm
- Dec 5, 2025: Jay R. Luly (President and CEO) sold 4,743 shares, about $67,493. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000057/0002064832-25-000057-index.htm
- Dec 2, 2025: Kathleen S. Capps (See Remarks) sold 207 shares, about $2,890. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000053/0002064832-25-000053-index.htm
- Dec 2, 2025: Harry R. Trout III (See Remarks) sold 380 shares, about $5,305. Source: https://www.sec.gov/Archives/edgar/data/1177648/000206483225000050/0002064832-25-000050-index.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
- 10-K filed Nov 19, 2025: https://www.sec.gov/Archives/edgar/data/1177648/000119312525288121/enta-20250930.htm
- 10-Q filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/enta-20260630.htm
- DEF 14A filed Jan 26, 2026: https://www.sec.gov/Archives/edgar/data/1177648/000119312526022558/enta-20260126.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/